Treatment with the probiotic VSL#3 as an adjunctive therapy in relapsing mild-to-moderate ulcerative colitis significantly reduces ulcerative colitis disease activity

Treatment with the probiotic VSL#3 as an adjunctive therapy in relapsing mild-to-moderate ulcerative colitis significantly reduces ulcerative colitis disease activity

Commentary on: TursiABrandimarteGPapaA. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010;105:2218–27.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ evidence-based medicine 2011-08, Vol.16 (4), p.108-109
Hauptverfasser: Turcotte, Jean-François, Huynh, Hien Q
Format: Artikel
Sprache:eng
Schlagworte:
Inflammatory bowel disease
Probiotics
Response rates
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Commentary on: TursiABrandimarteGPapaA. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010;105:2218–27.
ISSN:1356-5524
2515-446X
1473-6810
2515-4478
DOI:10.1136/ebm1189